Cheng, R., Kittleson, M. M., Wechalekar, A. D., Alvarez-Cardona, J., Mitchell, J. D., Scarlatelli Macedo, A. V., Dutra, J. P. P., Campbell, C. M., Liu, J. E., Landau, H. J., Davis, M. K., Morrissey, S., Casselli, S., Lousada, I., Seabra-Garcez, J. D., Szor, R. S., Ganatra, S., Trachtenberg, B., Maurer, M. S., … Lenihan, D. (2024). Moving towards establishing centres of excellence in cardiac amyloidosis: an International Cardio-Oncology Society statement. Heart, 110(12), 823–830. https://doi.org/10.1136/heartjnl-2023-323502

Ruberg, F. L., & Maurer, M. S. (2024). Cardiac Amyloidosis Due to Transthyretin Protein. JAMA, 331(9), 778. https://doi.org/10.1001/jama.2024.0442

Joseph‐Mathurin, N., Feldman, R. L., Lu, R., Shirzadi, Z., Toomer, C., Saint Clair, J. R., Ma, Y., McKay, N. S., Strain, J. F., Kilgore, C., Friedrichsen, K. A., Chen, C. D., Gordon, B. A., Chen, G., Hornbeck, R. C., Massoumzadeh, P., McCullough, A. A., Wang, Q., … Li, Y. (2024). Presenilin‐1 mutation position influences amyloidosis, small vessel disease, and dementia with disease stage. Alzheimer’s & Dementia, 20(4), 2680–2697. Portico. https://doi.org/10.1002/alz.13729

Niraula, S., Yan, S. S., & Subramanian, J. (2023). Amyloid Pathology Impairs Experience-Dependent Inhibitory Synaptic Plasticity. The Journal of Neuroscience, 44(5), e0702232023. https://doi.org/10.1523/jneurosci.0702-23.2023

Shah, S. J., Fine, N., Garcia-Pavia, P., Klein, A. L., Fernandes, F., Weissman, N. J., Maurer, M. S., Boman, K., Gundapaneni, B., Sultan, M. B., & Elliott, P. (2024). Effect of Tafamidis on Cardiac Function in Patients With Transthyretin Amyloid Cardiomyopathy. JAMA Cardiology, 9(1), 25. https://doi.org/10.1001/jamacardio.2023.4147

Miller, P., Maurer, M. S., Einstein, A. J., Elias, P., & Poterucha, T. J. (2023). Recognizing Cardiac Amyloidosis Phenotype by Echocardiography Increases Downstream Testing. Journal of the American Society of Echocardiography, 36(12), 1326–1329. https://doi.org/10.1016/j.echo.2023.08.018

Chan, N., Einstein, A. J., Griffin, J. M., Rosenblum, H., Teruya, S., Cuomo, M., De Los Santos, J., DeLuca, A., Johnson, L. L., Kinkhabwala, M. P., Leb, J. S., Mintz, A., Fine, D., Helmke, S., Muralidhar, V., Pandey, S., Sabogal, N., Saith, S. E., Winburn, M., … Maurer, M. S. (2023). Prevalence and significance of extracardiac uptake on pyrophosphate imaging in the SCAN-MP study: the first 379 cases. Journal of Nuclear Cardiology, 30(6), 2531–2539. https://doi.org/10.1007/s12350-023-03310-7

Maurer, M. S., Kale, P., Fontana, M., Berk, J. L., Grogan, M., Gustafsson, F., Hung, R. R., Gottlieb, R. L., Damy, T., González-Duarte, A., Sarswat, N., Sekijima, Y., Tahara, N., Taylor, M. S., Kubanek, M., Donal, E., Palecek, T., Tsujita, K., Tang, W. H. W., … Gillmore, J. D. (2023). Patisiran Treatment in Patients with Transthyretin Cardiac Amyloidosis. New England Journal of Medicine, 389(17), 1553–1565. https://doi.org/10.1056/nejmoa2300757

Chakraborty, R., Milani, P., Palladini, G., & Gertz, M. (2023). Role of autologous haematopoietic cell transplantation in the treatment of systemic light chain amyloidosis in the era of anti-CD38 monoclonal antibodies. The Lancet Haematology, 10(11), e936–e940. https://doi.org/10.1016/s2352-3026(23)00175-8

Pandey, S., Teruya, S., Rodriguez, C., Deluca, A., Kinkhabwala, M., Johnson, L. L., Fine, D., Sabogal, N., Winburn, M., Castillo, M., Bhatia, K., Malkovskaya, R., Raiszadeh, F., Kurian, D., Miller, E. J., Einstein, A. J., Maurer, M. S., & Ruberg, F. L. (2023). Diagnostic performance characteristics of planar quantitative and semi-quantitative parameters of Tc99m pyrophosphate (PYP) imaging for diagnosis of transthyretin (ATTR) cardiac amyloidosis: the SCAN-MP study. Journal of Nuclear Cardiology, 30(4), 1414–1419. https://doi.org/10.1007/s12350-023-03203-9

Madhani, A., Sabogal, N., Massillon, D., Paul, L. D., Rodriguez, C., Fine, D., Helmke, S., Winburn, M., Kurian, D., Raiszadeh, F., Teruya, S., Cohn, E., Einstein, A. J., Miller, E. J., Connors, L. H., Maurer, M. S., & Ruberg, F. L. (2023). Clinical Penetrance of the Transthyretin V122I Variant in Older Black Patients With Heart Failure: The SCAN‐MP (Screening for Cardiac Amyloidosis With Nuclear Imaging in Minority Populations) Study. Journal of the American Heart Association, 12(15). https://doi.org/10.1161/jaha.122.028973

Smiley, D. A., Einstein, A. J., Mintz, A., Shetty, M., Chan, N., Helmke, S. T., Bhatia, K., Goldner, K., Brannagan, T. H., Santana, D. D., & Maurer, M. S. (2023). Gene Silencing Therapy in Hereditary (Variant) Transthyretin Cardiac Amyloidosis: A Puzzling Case of Decreasing Pyrophosphate Uptake on Scintigraphy. Circulation: Cardiovascular Imaging, 16(8). https://doi.org/10.1161/circimaging.123.015243

Shetty, M., & Malhotra, S. (2023). Novel Tracers for the Imaging of Cardiac Amyloidosis. Journal of Nuclear Medicine Technology, 51(2), 120–124. https://doi.org/10.2967/jnmt.123.265568

Smiley, D., Einstein, A. J., Chan, N., Mintz, A., Santana, D. D., Shetty, M., Sekulic, M., Goldner, K., Wall, J., Helmke, S., & Maurer, M. S. (2023). In the thick of it: hereditary cardiac amyloidosis identified by 124I-AT-01 PET imaging but not cardiac MRI or SPECT 99mTc pyrophosphate scintigraphy. Journal of Nuclear Cardiology, 30(3), 1258–1262. https://doi.org/10.1007/s12350-023-03267-7

Basdavanos, A., Maurer, M. S., Ives, L., Derwin, K., Ricchetti, E. T., Seitz, W., & Hanna, M. (2023). Prevalence of Orthopedic Manifestations in Patients With Cardiac Amyloidosis With a Focus on Shoulder Pathologies. The American Journal of Cardiology, 190, 67–74. https://doi.org/10.1016/j.amjcard.2022.11.014

Muchtar, E., Dispenzieri, A., Wisniowski, B., Palladini, G., Milani, P., Merlini, G., Schönland, S., Veelken, K., Hegenbart, U., Geyer, S. M., Kumar, S. K., Kastritis, E., Dimopoulos, M. A., Liedtke, M., Witteles, R., Sanchorawala, V., Szalat, R., Landau, H., Petrlik, E., … Gertz, M. A. (2023). Graded Cardiac Response Criteria for Patients With Systemic Light Chain Amyloidosis. Journal of Clinical Oncology, 41(7), 1393–1403. https://doi.org/10.1200/jco.22.00643

Sperry, B. W., Hanna, M., Maurer, M. S., Nativi-Nicolau, J., Floden, L., Stewart, M., Wyrwich, K. W., Barsdorf, A. I., Kapadia, H., & Spertus, J. A. (2023). Association of Tafamidis With Health Status in Patients With ATTR Cardiac Amyloidosis. JAMA Cardiology, 8(3), 275. https://doi.org/10.1001/jamacardio.2022.5251

Chan, N., HANNA, M., & MAURER, M. S. (2023). The Wiggers Diagram: Hemodynamic Changes in Cardiac Amyloidosis. Journal of Cardiac Failure, 29(2), 217–219. https://doi.org/10.1016/j.cardfail.2022.06.008

Yogeswaran, V., Singulane, C. C., Slivnick, J. A., Kirkpatrick, J. N., Addetia, K., Lang, R. M., Vasbinder, A., Liu, J. E., Maurer, M. S., & Cheng, R. K. (2023). Multichamber Strain Predicts Atrial Fibrillation in Cardiac Amyloidosis. Journal of the American Society of Echocardiography, 36(2), 257–259. https://doi.org/10.1016/j.echo.2022.10.010

Maurer, M. S., Smiley, D., Simsolo, E., Remotti, F., Bustamante, A., Teruya, S., Helmke, S., Einstein, A. J., Lehman, R., Giles, J. T., Kelly, J. W., Tsai, F., Blaner, W. S., Brun, P., Riesenburger, R. I., Kryzanski, J., Varga, C., & Patel, A. R. (2022). Analysis of lumbar spine stenosis specimens for identification of amyloid. Journal of the American Geriatrics Society, 70(12), 3538–3548. Portico. https://doi.org/10.1111/jgs.17976

Smiley, D. A., Rodriguez, C. M., & Maurer, M. S. (2022). Transthyretin Cardiac Amyloidosis. Cardiology Clinics, 40(4), 541–558. https://doi.org/10.1016/j.ccl.2022.06.008

Morris, J. C., Weiner, M., Xiong, C., Beckett, L., Coble, D., Saito, N., Aisen, P. S., Allegri, R., Benzinger, T. L. S., Berman, S. B., Cairns, N. J., Carrillo, M. C., Chui, H. C., Chhatwal, J. P., Cruchaga, C., Fagan, A. M., Farlow, M., Fox, N. C., Ghetti, B., … Buckles, V. D. (2022). Autosomal dominant and sporadic late onset Alzheimer’s disease share a commonin vivopathophysiology. Brain, 145(10), 3594–3607. https://doi.org/10.1093/brain/awac181

Bäcker, H. C., Galle, S. E., Lentzsch, S., Freibott, C. E., Shoap, S., Strauch, R. J., & Rosenwasser, M. P. (2021). Flexor tenosynovectomy in carpal tunnel syndrome as a screening tool for early diagnosis of amyloidosis. Irish Journal of Medical Science (1971 -), 191(5), 2427–2430. https://doi.org/10.1007/s11845-021-02832-8

Miller, E. J., Campisi, R., Shah, N. R., McMahon, S., Cuddy, S., Gallegos-Kattan, C., Maurer, M. S., Damy, T., Slart, R. H. J. A., Bhatia, K., & Einstein, A. J. (2022). Radiopharmaceutical supply disruptions and the use of 99mTc-hydroxymethylene diphosphonate as an alternative to 99mTc-pyrophosphate for the diagnosis of transthyretin cardiac amyloidosis: An ASNC Information Statement. Journal of Nuclear Cardiology, 29(5), 2748–2760. https://doi.org/10.1007/s12350-022-03059-5

Javaugue, V., Rocha, A. B., Said, S. M., Santoriello, D., Hou, J., Dasari, S., Theis, J. D., Vrana, J. A., Batal, I., Larsen, C., Markowitz, G. S., D’Agati, V. D., McPhail, E. D., Leung, N., & Nasr, S. H. (2022). Clinicopathologic and proteomic characteristics of intratubular cytoplasmic AL amyloidosis. Kidney International, 102(4), 926–929. https://doi.org/10.1016/j.kint.2022.07.020

Westin, O., Fosbøl, E. L., Maurer, M. S., Leicht, B. P., Hasbak, P., Mylin, A. K., Rørvig, S., Lindkær, T. H., Johannesen, H. H., & Gustafsson, F. (2022). Screening for Cardiac Amyloidosis 5 to 15 Years After Surgery for Bilateral Carpal Tunnel Syndrome. Journal of the American College of Cardiology, 80(10), 967–977. https://doi.org/10.1016/j.jacc.2022.06.026

Lao, P. J., Boehme, A. K., Morales, C., Laing, K. K., Chesebro, A., Igwe, K. C., Gutierrez, J., Gu, Y., Stern, Y., Schupf, N., Manly, J. J., Mayeux, R., & Brickman, A. M. (2022). Amyloid, cerebrovascular disease, and neurodegeneration biomarkers are associated with cognitive trajectories in a racially and ethnically diverse, community-based sample. Neurobiology of Aging, 117, 83–96. https://doi.org/10.1016/j.neurobiolaging.2022.05.004

Westin, O. M., Butt, J. H., Gustafsson, F., Køber, L., Vinther, M., Maurer, M. S., & Fosbøl, E. L. (2022). Carpal Tunnel Syndrome in Patients Who Underwent Pacemaker Implantation and Relation to Amyloidosis, Heart Failure, and Mortality. The American Journal of Cardiology, 177, 121–127. https://doi.org/10.1016/j.amjcard.2022.04.059

Lin, H., Zhang, X., Einstein, A. J., & Tang, G. (2022). Serial Tc-99m MDP scintigraphy demonstrating increasing cardiac uptake over time in a patient with light-chain cardiac amyloidosis. Journal of Nuclear Cardiology, 29(4), 2024–2028. https://doi.org/10.1007/s12350-022-02987-6

Lee, A. J., Raghavan, N. S., Bhattarai, P., Siddiqui, T., Sariya, S., Reyes-Dumeyer, D., Flowers, X. E., Cardoso, S. A. L., De Jager, P. L., Bennett, D. A., Schneider, J. A., Menon, V., Wang, Y., Lantigua, R. A., Medrano, M., Rivera, D., Jiménez-Velázquez, I. Z., Kukull, W. A., Brickman, A. M., … Mayeux, R. (2022). FMNL2 regulates gliovascular interactions and is associated with vascular risk factors and cerebrovascular pathology in Alzheimer’s disease. Acta Neuropathologica, 144(1), 59–79. https://doi.org/10.1007/s00401-022-02431-6

Maurer, M. S., Dunnmon, P., Fontana, M., Quarta, C. C., Prasad, K., Witteles, R. M., Rapezzi, C., Signorovitch, J., Lousada, I., & Merlini, G. (2022). Proposed Cardiac End Points for Clinical Trials in Immunoglobulin Light Chain Amyloidosis: Report From the Amyloidosis Forum Cardiac Working Group. Circulation: Heart Failure, 15(6). https://doi.org/10.1161/circheartfailure.121.009038

Batra, J., Rosenblum, H., Cappelli, F., Zampieri, M., Olivotto, I., Griffin, J. M., Saith, S. E., Teruya, S., De Los Santos, J., Argiro, A., Burkhoff, D., Perfetto, F., & Maurer, M. S. (2022). Racial Differences in Val122Ile-Associated Transthyretin Cardiac Amyloidosis. Journal of Cardiac Failure, 28(6), 950–959. https://doi.org/10.1016/j.cardfail.2021.12.016

Kim, H., Levine, A., Cohen, D., Gehrman, P., Zhu, X., Devanand, D. P., Lee, S., & Goldberg, T. E. (2022). The Role of Amyloid, Tau, and APOE Genotype on the Relationship Between Informant-Reported Sleep Disturbance and Alzheimer’s Disease Risks. Journal of Alzheimer’s Disease, 87(4), 1567–1580. https://doi.org/10.3233/jad-215417

Rapezzi, C., Aimo, A., Serenelli, M., Barison, A., Vergaro, G., Passino, C., Panichella, G., Sinagra, G., Merlo, M., Fontana, M., Gillmore, J., Quarta, C. C., Maurer, M. S., Kittleson, M. M., Garcia-Pavia, P., & Emdin, M. (2022). Critical Comparison of Documents From Scientific Societies on Cardiac Amyloidosis. Journal of the American College of Cardiology, 79(13), 1288–1303. https://doi.org/10.1016/j.jacc.2022.01.036

Cuddy, S. A. M., Jerosch-Herold, M., Falk, R. H., Kijewski, M. F., Singh, V., Ruberg, F. L., Sanchorawala, V., Landau, H., Maurer, M. S., Yee, A. J., Bianchi, G., Di Carli, M. F., Liao, R., Kwong, R. Y., & Dorbala, S. (2022). Myocardial Composition in Light-Chain Cardiac Amyloidosis More Than 1 Year After Successful Therapy. JACC: Cardiovascular Imaging, 15(4), 594–603. https://doi.org/10.1016/j.jcmg.2021.09.032

Jansen, W. J., Janssen, O., Tijms, B. M., Vos, S. J. B., Ossenkoppele, R., Visser, P. J., Aarsland, D., Alcolea, D., Altomare, D., von Arnim, C., Baiardi, S., Baldeiras, I., Barthel, H., Bateman, R. J., Van Berckel, B., Binette, A. P., Blennow, K., Boada, M., … Zetterberg, H. (2022). Prevalence Estimates of Amyloid Abnormality Across the Alzheimer Disease Clinical Spectrum. JAMA Neurology, 79(3), 228. https://doi.org/10.1001/jamaneurol.2021.5216